With the introduction of Immunotherapies as a treatment option in the treatment of Malignant Melanoma, very good results have been achieved. However, a significant proportion of patients may develop resistance to treatment. Comprehensive analyses can provide valuable results in determining treatment resistance. In addition, comprehensive genetic analysis plays an extremely important role in the suitability of other targeting therapies (BRAF and MEK Inhibitors).